147 related articles for article (PubMed ID: 37690873)
21. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
Laufer RS; Driscoll AJ; Baral R; Buchwald AG; Campbell JD; Coulibaly F; Diallo F; Doumbia M; Galvani AP; Haidara FC; Kotloff KL; Keita AM; Neuzil KM; Orenstein EW; Orenstein LAV; Pecenka C; Sow S; Tapia MD; Ortiz JR; Fitzpatrick MC
Vaccine; 2021 Aug; 39(35):5037-5045. PubMed ID: 34325934
[TBL] [Abstract][Full Text] [Related]
23. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan.
Ishiwada N; Akaishi R; Kobayashi Y; Togo K; Yonemoto N; Matsuo M; Kaneko S; Law AW; Kamei K
Infect Dis Ther; 2024 Jul; 13(7):1665-1682. PubMed ID: 38834858
[TBL] [Abstract][Full Text] [Related]
25. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
[TBL] [Abstract][Full Text] [Related]
26. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.
Srikantiah P; Klugman KP
BMC Med; 2023 May; 21(1):177. PubMed ID: 37183242
[TBL] [Abstract][Full Text] [Related]
27. Nirsevimab: A Review.
Balbi H
Pediatr Allergy Immunol Pulmonol; 2024 Mar; 37(1):3-6. PubMed ID: 38484270
[TBL] [Abstract][Full Text] [Related]
28. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
[TBL] [Abstract][Full Text] [Related]
29. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study.
Li X; Hodgson D; Flaig J; Kieffer A; Herring WL; Beyhaghi H; Willem L; Jit M; Bilcke J; Beutels P;
Value Health; 2023 Apr; 26(4):508-518. PubMed ID: 36442831
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
[TBL] [Abstract][Full Text] [Related]
33. Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults.
Athan E; Baber J; Quan K; Scott RJ; Jaques A; Jiang Q; Li W; Cooper D; Cutler MW; Kalinina EV; Anderson AS; Swanson KA; Gruber WC; Gurtman A; Schmoele-Thoma B;
Clin Infect Dis; 2024 May; 78(5):1360-1368. PubMed ID: 37992000
[TBL] [Abstract][Full Text] [Related]
34. Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach.
Pan-Ngum W; Kinyanjui T; Kiti M; Taylor S; Toussaint JF; Saralamba S; Van Effelterre T; Nokes DJ; White LJ
Vaccine; 2017 Jan; 35(2):403-409. PubMed ID: 27914740
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States.
Yu T; Padula WV; Yieh L; Gong CL
Pediatr Neonatol; 2024 Mar; 65(2):152-158. PubMed ID: 37758594
[TBL] [Abstract][Full Text] [Related]
36. Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody.
Treston B; Geoghegan S
Hum Vaccin Immunother; 2024 Dec; 20(1):2341505. PubMed ID: 38723786
[TBL] [Abstract][Full Text] [Related]
37. Exploratory analysis of the economically justifiable price of nirsevimab for healthy late-preterm and term infants in Colombia.
Buendía JA; Acuña-Cordero R; Rodriguez-Martinez CE
Pediatr Pulmonol; 2024 May; 59(5):1372-1379. PubMed ID: 38358037
[TBL] [Abstract][Full Text] [Related]
38. Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis.
Laufer RS; Baral R; Buchwald AG; Campbell JD; Coulibaly F; Diallo F; Doumbia M; Driscoll AJ; Galvani AP; Keita AM; Neuzil KM; Sow S; Pecenka C; Ortiz JR; Fitzpatrick MC
PLOS Glob Public Health; 2023; 3(5):e0001432. PubMed ID: 37145993
[TBL] [Abstract][Full Text] [Related]
39. Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
Simões EAF; Center KJ; Tita ATN; Swanson KA; Radley D; Houghton J; McGrory SB; Gomme E; Anderson M; Roberts JP; Scott DA; Jansen KU; Gruber WC; Dormitzer PR; Gurtman AC
N Engl J Med; 2022 Apr; 386(17):1615-1626. PubMed ID: 35476650
[TBL] [Abstract][Full Text] [Related]
40. Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
Ren S; Chen Q; Zhang Y; Yi L; Qian C; Lu Y; Shen J; Liu X; Jiang M; Wang B; Song J; Shao X; Zhang T; Tian J; Zhao G
Vaccine; 2024 Jan; 42(2):352-361. PubMed ID: 38057209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]